Patents by Inventor Michael F. Giblin

Michael F. Giblin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
    Patent number: 6680045
    Abstract: A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: January 20, 2004
    Assignee: The Curators of the University of Missouri
    Inventors: Silvia S. Jurisson, Thomas P. Quinn, Michael F. Giblin
  • Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma
    Patent number: 6607709
    Abstract: A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: August 19, 2003
    Assignee: The Curators of the University of Missouri
    Inventors: Silvia S. Jurisson, Thomas P. Quinn, Michael F. Giblin
  • Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
    Patent number: 6338834
    Abstract: A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.
    Type: Grant
    Filed: April 30, 1998
    Date of Patent: January 15, 2002
    Assignee: The Curators of the University of Missouri
    Inventors: Silvia S. Jurisson, Thomas P. Quinn, Michael F. Giblin
  • Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
    Publication number: 20010038822
    Abstract: A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.
    Type: Application
    Filed: April 24, 2001
    Publication date: November 8, 2001
    Inventors: Silvia S. Jurisson, Thomas P. Quinn, Michael F. Giblin